Literature DB >> 30895428

Investigating the Survival Benefit of Combining Radiotherapy for Surgery Treated Locally Advanced Esophageal Squamous Cell Carcinoma Patients Aged 65 and Older.

Shan Huang1, Yuxing Li2, Hongbing Ma2, Wenyu Wang3, Shuyu Zheng3, Yue Ke2, Fang Li2.   

Abstract

PURPOSE: To evaluate the survival benefit of combining radiotherapy with surgery in locally advanced esophageal squamous cell carcinoma (ESCC) patients aged over 65.
METHODS: Using the SEER database, we selected patients age ≥ 65 years that were diagnosed as locally advanced ESCC during 2004-2013. Cancer-specific survival (CSS) was examined using the Kaplan-Meier analysis and compared by the log-rank test. Univariable and multivariable Cox proportional hazard models were established to identify possible prognostic factors.
RESULTS: A total of 972 cases were included in the study. For surgical patients aged 65-79 years, 74 patients (32.9%) were treated by surgery alone and 122 patients (54.2%) had received additional neoadjuvant radiotherapy (NRT). NRT + surgery was associated with improved CSS comparing with surgery alone (HR, 0.58; 95%CI, 0.39 to 0.85; P = 0.005). In subgroup analysis, NRT was associated with improved CSS for patients aged 65-74 years (2-year CSS 56.6% versus 39.6%, P = 0.026). No significant differences of progonosis was observed for different treatment groups in 75-79 years patients (P = 0.972).
CONCLUSIONS: In this SEER-based study, the addition of neoadjuvant radiotherapy before surgery was associated with improved CSS for locally advanced ESCC patients aged 65 to 74 years.

Entities:  

Keywords:  Aged 65 and older; Esophageal squamous cell carcinoma; Radiotherapy; Surgery; Survival

Year:  2019        PMID: 30895428     DOI: 10.1007/s11605-019-04200-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  13 in total

1.  Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study.

Authors:  J M Daly; W A Fry; A G Little; D P Winchester; R F McKee; A K Stewart; A M Fremgen
Journal:  J Am Coll Surg       Date:  2000-05       Impact factor: 6.113

2.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

3.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

Authors:  Christophe Mariette; Laetitia Dahan; Françoise Mornex; Emilie Maillard; Pascal-Alexandre Thomas; Bernard Meunier; Valérie Boige; Denis Pezet; William B Robb; Valérie Le Brun-Ly; Jean-François Bosset; Jean-Yves Mabrut; Jean-Pierre Triboulet; Laurent Bedenne; Jean-François Seitz
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

4.  Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients.

Authors:  Ze Fen Xiao; Zong Yi Yang; Jun Liang; Yan Jun Miao; Mei Wang; Wei Bo Yin; Xian Zhi Gu; De Chao Zhang; Ru Gang Zhang; Liang Jun Wang
Journal:  Ann Thorac Surg       Date:  2003-02       Impact factor: 4.330

5.  Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older.

Authors:  R H Mak; H J Mamon; D P Ryan; D T Miyamoto; M Ancukiewicz; W K Kobayashi; C G Willett; N C Choi; L S Blaszkowsky; T S Hong
Journal:  Dis Esophagus       Date:  2009-09-24       Impact factor: 3.429

Review 6.  Oesophageal carcinoma.

Authors:  Arjun Pennathur; Michael K Gibson; Blair A Jobe; James D Luketich
Journal:  Lancet       Date:  2013-02-02       Impact factor: 79.321

7.  Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study.

Authors:  M Fok; J S Sham; D Choy; S W Cheng; J Wong
Journal:  Surgery       Date:  1993-02       Impact factor: 3.982

Review 8.  Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years.

Authors:  Yan Zheng; Yin Li; Xianben Liu; Haibo Sun; Zongfei Wang; Ruixiang Zhang
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

9.  Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older.

Authors:  Shan Huang; Shuyu Zheng; Tuotuo Gong; Hongbing Ma; Yue Ke; Songchuan Zhao; Wenyu Wang; Lijun Jia; Xiaozhi Zhang
Journal:  Oncotarget       Date:  2017-12-04

10.  Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.

Authors:  Hong Yang; Hui Liu; Yuping Chen; Chengchu Zhu; Wentao Fang; Zhentao Yu; Weimin Mao; Jiaqing Xiang; Yongtao Han; Zhijian Chen; Haihua Yang; Jiaming Wang; Qingsong Pang; Xiao Zheng; Huanjun Yang; Tao Li; Florian Lordick; Xavier Benoit D'Journo; Robert J Cerfolio; Robert J Korst; Nuria M Novoa; Scott J Swanson; Alessandro Brunelli; Mahmoud Ismail; Hiran C Fernando; Xu Zhang; Qun Li; Geng Wang; Baofu Chen; Teng Mao; Min Kong; Xufeng Guo; Ting Lin; Mengzhong Liu; Jianhua Fu
Journal:  J Clin Oncol       Date:  2018-08-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.